Jaguar Health Inc (JAGX) News & EventsJAGXJaguar Health Inc

Jaguar Health Files $75M Mixed Securities Shelf

Jaguar Health files $75M mixed securities shelf

Jaguar Health Continues Providing Oral Crofelemer Powder for Pediatric Patient

Jaguar Health announced that Jaguar family company Napo Pharmaceuticals has been continuing to provide the company's novel crofelemer powder for oral solution for several weeks for the treatment of intestinal failure in an infant patient with GUCY2C mutation resulting in congenital sodium diarrhea. Liquid oral crofelemer therapy is well tolerated by this patient and has demonstrated reduced needs for daily and weekly parenteral support with no significant clinical or laboratory abnormalities. CSD due to mutation of the GUCY2C gene is the third IF-related congenital enteropathy being evaluated under expanded access, in addition to pediatric microvillus inclusion disease and short bowel syndrome, for which crofelemer has demonstrated benefit in reducing weekly parenteral support needs normalized to body weight. The company plans to file a New Drug Application for crofelemer for MVID in mid-2027 to obtain FDA approval based on data that will include results from an ongoing pivotal trial which has completed enrollment. Patients with IF, including those with short bowel syndrome or MVID, cannot orally absorb adequate nutrients, electrolytes and fluids, and require lifelong total parenteral nutrition with or without supplemental intravenous fluids, which together comprise parenteral support, for up to seven days per week and up to 20+ hours per day. While PS is supportive and lifesaving, it is associated with serious, sometimes fatal complications. Pediatric CSD patients with GUCY2C mutation have a significant challenge for managing nutritional and electrolyte deficiencies, given the higher impact on growth and developmental needs. This pediatric patient with IF due to CSD requires significant daily PS, and liquid oral crofelemer therapy has reduced their daily PS needs by approximately 15% within the first several weeks, consistent with what was observed in pediatric IF patients with MVID and SBS.

Jaguar Health Announces Special Stock Dividend Payment Date

Jaguar Health provided an update in connection with the company's previously announced special stock dividend, which is payable on October 15 to holders of Jaguar common stock and certain outstanding warrants as of record on October 13, to announce that Nasdaq has indicated that the ex-dividend date for the special stock dividend is October 16. The special stock dividend consists of the company's Series R Convertible Preferred Stock. Nasdaq has advised the company that its shares of common stock will trade with "due bills" representing an assignment of the right to receive the dividend from the record date of October 13 until the ex-dividend date. Stockholders who sell their shares of common stock during the dividend right period will be selling their right to the special stock dividend. "Jaguar is issuing the Special Stock Dividend to reward and recognize our passionate and supportive stockholders and provide protection against potential dilution as we continue evaluation of strategic alternatives," said Lisa Conte, Jaguar's founder, president, and CEO.